Rachel Leskowitz
A5090569264- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Insect Resistance and Genetics
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- CRISPR and Genetic Engineering
- Immunotherapy and Immune Responses
- Nanofabrication and Lithography Techniques
- Biosimilars and Bioanalytical Methods
- Nanowire Synthesis and Applications
University of Pennsylvania
2022-2025
Abstract We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, N = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects measurable disease, 10 exhibited partial...
The use of lentiviral vectors in cell and gene therapy is steadily increasing, both commercial investigational therapies. Although existing data increasingly support the usefulness safety clinical-grade used manufacturing, comprehensive studies specifically addressing their long-term stability are currently lacking. This significant considering high cost producing testing GMP-grade vectors, limited number production facilities, lengthy queue for slots. Therefore, an extended shelf life a...
<div>Abstract<p>We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, <i>N</i> = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects...
<div>Abstract<p>We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, <i>N</i> = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects...